Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. 在 2026年8月5日 公布了什么

截至 2026年6月30日 的季度，与去年同季度相比。

这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。

对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。

业绩电话会

暂无 Recursion Pharmaceuticals, Inc. 的业绩电话会文字记录。

管理层说了什么

“Recursion has reached a pivotal point where our AI-native platform is translating unique data into potential first-in-class therapeutic opportunities,”

逐字引自公告，且只在文件将其归于具名人士时才展示。

股价作何反应

公告在收盘后或开盘前发布，因此这里的变动是随后的那个交易日。

Recursion Pharmaceuticals, Inc. 做什么

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting. Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.

公司自己的描述，取自公告末尾。